TY - JOUR
T1 - BPH
T2 - Why Do Patients Fail Medical Therapy?
AU - Gul, Zeynep G.
AU - Kaplan, Steven A.
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Purpose of Review: In this article, we review why patients may fail medical therapy for benign prostatic hyperplasia (BPH) and by doing so, gain a better understanding of the disease process and how to optimize the care of these patients. Recent Findings: A growing body of literature has attempted to better characterize the various mechanisms by which patients develop BPH as well as identify predictors of disease progression and treatment failure. Summary: BPH is a heterogenous disease process. A more personalized approach to treatment, including patient selection for medical or surgical management, would allow us to optimize patient care.
AB - Purpose of Review: In this article, we review why patients may fail medical therapy for benign prostatic hyperplasia (BPH) and by doing so, gain a better understanding of the disease process and how to optimize the care of these patients. Recent Findings: A growing body of literature has attempted to better characterize the various mechanisms by which patients develop BPH as well as identify predictors of disease progression and treatment failure. Summary: BPH is a heterogenous disease process. A more personalized approach to treatment, including patient selection for medical or surgical management, would allow us to optimize patient care.
KW - 5alpha-reductase inhibitors
KW - Alpha-blockers
KW - Benign prostatic hyperplasia
KW - Clinical trial results
KW - Medical therapy
KW - Predictors of treatment failure
UR - http://www.scopus.com/inward/record.url?scp=85066845266&partnerID=8YFLogxK
U2 - 10.1007/s11934-019-0899-z
DO - 10.1007/s11934-019-0899-z
M3 - Review article
C2 - 31168725
AN - SCOPUS:85066845266
SN - 1527-2737
VL - 20
JO - Current urology reports
JF - Current urology reports
IS - 7
M1 - 40
ER -